^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HPB-092

    i
    Other names: HPB-092
    Company:
    Polymed Biopharma
    Drug class:
    FLT3 inhibitor, IRAK-4 inhibitor
    Related drugs:
    1year
    A novel and potent FLT3 and IRAK4 dual inhibitor for the treatment of acute myeloid leukemia (AACR 2023)
    Emavusertib (CA-4948), an IRAK4/FLT3 inhibitor, is currently in phase I clinical trials. In addition, no rhabdomyolysis side-effect was observed upon histological analysis. These results underscore the potential therapeutic benefit and safety profile of HPB-092 for the treatment of AML, especially in patients with mutations in U2AF1 or SFF3B1 spliceosome.
    IO biomarker
    |
    FLT3 (Fms-related tyrosine kinase 3) • SF3B1 (Splicing Factor 3b Subunit 1) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
    |
    FLT3 mutation • U2AF1 mutation
    |
    emavusertib (CA-4948) • HPB-092